Author:
Marshall-McKenna R.,Morrison A.,Stirling L.,Hutchison C.,Rice A. M.,Hewitt C.,Paul L.,Rodger M.,Macpherson I. R.,McCartney E.
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Lifetime risk was calculated using 2010 data for females and 2008–2010 data for males by the Statistical Information Team at Cancer Research UK, 2012. Available at:
2. Schiavon G, Smith IE (2014) Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res 16:206. doi: 10.1186/bcr3636
3. Fenlon DR, Corner JL, Haviland J (2009) Menopausal hot flushes after breast cancer. Eur J Cancer Care 18:140–148
4. McCowan C, Tompson AM (2012) The importance of nonpharmacogenetic factors in endocrine therapy. Pharmacogenomics 13(6):721–728
5. MCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. BJC 99:1763–1768
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献